磁共振成像检查诊断子宫肌瘤的临床价值

Clinical Value of Magnetic Resonance Imaging Examination in the Diagnosis of Uterine Myoma

目的:分析子宫肌瘤(uterine myoma,UM)诊断中使用磁共振成像(MRI)检查的价值。方法:从2021年3月—2022年3月在仁怀市人民医院就诊的疑似UM患者中随机抽取56例,所有患者均接受MRI、多层螺旋CT(MSCT)、病理检查。以病理检查结果为金标准,记录MRI、MSCT诊断结果,并对比MRI、MSCT诊断效能。结果:病理诊断的阳性率为89.28%,阴性率为10.72%;MRI诊断的阳性率为82.14%,阴性率为17.86%,MSCT诊断的阳性率为62.50%,阴性率为37.50%。MRI诊断阳性率高于MSCT(χ^(2)=5.397,P=0.020)。MRI诊断UM的敏感度、准确度均高于MSCT诊断(P<0.05);两种诊断的特异度比较,差异无统计学意义(P>0.05)。MRI诊断UM类型的敏感度比较,差异均无统计学意义(P>0.05);MRI诊断UM类型的特异度(除玻璃样变)、准确度均高于MSCT诊断(P<0.05)。结论:UM诊断中使用MRI具有较高的诊断效能,能根据MRI信号特点将UM类型区分出来,从而为后续治疗方案地制订提供更加科学的参考依据。

Objective:To analyze the value of magnetic resonance imaging(MRI)examination in the diagnosis of uterine myoma(UM).Method:A total of 56 patients with suspected UM were randomly selected from March 2021 to March 2022 in Renhuai People's Hospital.All patients received MRI,multi-slice spiral(MSCT)and pathological examination.Using pathological examination results as the gold standard,the diagnostic results of MRI and MSCT were recorded,and the diagnostic efficacy of MRI and MSCT was compared.Result:The positive rate of pathological diagnosis was 89.28%and the negative rate was 10.72%,the positive rate of MRI diagnosis was 82.14%and the negative rate was 17.86%,and the positive rate of MSCT diagnosis was 62.50%and the negative rate was 37.50%.The positive rate of MRI was higher than that of MSCT(χ^(2)=5.397,P=0.020).The sensitivity and accuracy of MRI diagnosis were higher than those of MSCT diagnosis(P<0.05).There was no significant difference in the specificity of the two diagnoses(P>0.05).There were no significant difference in the sensitivity of MRI diagnosis of UM types(P>0.05).The specificity(except hyaline degeneration)and accuracy of MRI diagnosis of UM types were higher than that of MSCT diagnosis(P<0.05).Conclusion:The use of MRI in the diagnosis of UM has a high diagnostic efficiency,which can distinguish the types of UM according to the characteristics of MRI signals,thus providing a more scientific reference for the formulation of follow-up treatment.